ABT

$109.95

Market ClosedAs of Mar 16, 8:01 PM UTC

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$109.95
Potential Downside
30.3%
Whystock Fair Value$76.60
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medica...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$191.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Strong income play. Yield provides a meaningful total return floor.
229.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
12.96%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.02

Recent News

Simply Wall St.
Mar 17, 2026

Abbott Diabetes And Cardiology Updates Test Growth Story For Investors

Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system for people with Type 2 diabetes using basal insulin. The company also introduced its next generation XIENCE Skypoint drug eluting stent in India, expanding its interventional cardiology offering. These developments highlight fresh clinical data in diabetes care and a broader global rollout of Abbott’s cardiovascular technologies. At a share price of $109.95, Abbott...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barchart
Mar 16, 2026

This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 16, 2026

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

Abbott (ABT) closed at $109.95 in the latest trading session, marking a +1.78% move from the prior day.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 16, 2026

GEHC vs. ABT: Which Stock Is the Better Value Option?

GEHC vs. ABT: Which Stock Is the Better Value Option?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 15, 2026

Abbott Laboratories (ABT) Unveils XIENCE Skypoint to Advance Cardiovascular Treatment in India

Abbott Laboratories (NYSE:ABT) is one of Goldman Sachs top healthcare stocks. On March 10, Abbott Laboratories (NYSE:ABT) confirmed the launch of its most advanced generation stent, XIENCE Skypoint, in India. The launch is designed to equip doctors in the country with stents that can reach difficult areas and treat a wide range of blockages. XIENCE […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.